BiotechTube
Biomodal

Biomodal

Cambridge, United Kingdom· Est.
biomodal.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Biomodal is a private, pre-revenue platform company pioneering the analysis of the '6-base genome,' which integrates genetic sequence with key epigenetic modifications (5mC and 5hmC) from a single, low-input sample. Its flagship duet multiomics solution (evoC and +modC) and associated software (modality XPLR) aim to replace cumbersome, multi-workflow approaches, offering researchers higher accuracy and more integrated data. The company targets the rapidly growing multiomics and epigenetics research markets, with strong initial applications in oncology, neurodegenerative disease research, and liquid biopsy development.

OncologyNeurodegenerative DiseasesOther (Aging, Prenatal Health)

Technology Platform

Proprietary chemistry and bioinformatics for '6-base genome' sequencing, enabling simultaneous, single-workflow capture of genetic sequence and epigenetic modifications (5mC & 5hmC) from low-input DNA samples.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The growing demand for integrated multiomic data in complex disease research, particularly in liquid biopsy and early cancer detection, presents a major opportunity.
Biomodal's ability to differentiate 5hmC from 5mC addresses a specific need in epigenetics that could become a standard in research and eventually diagnostics.

Risk Factors

Key risks include competition from larger, established sequencing companies and other epigenomics startups, the challenge of convincing researchers to adopt a new workflow, and the technical risk associated with scaling and consistently delivering high-performance assays.
As a pre-revenue startup, it also faces significant financial and execution risks.

Competitive Landscape

Biomodal competes in the epigenomics and multiomics analysis space against large NGS players like Illumina (with methylation array and sequencing solutions) and PacBio (with long-read epigenetics), as well as numerous specialty startups (e.g., Twist Bioscience in target enrichment, Element Biosciences in sequencing). Its key differentiator is the single-workflow, simultaneous genetic/epigenetic analysis with 5mC/5hmC resolution.

More companies in United Kingdom →